Home / GNFTF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does GNFTF make money? Does GNFTF have pricing power? What's the Earnings Whisper? Will GNFTF profit more as the business scales? What is GNFTF's management track record? Is GNFTF's current price justified?

Genfit S.a.

$15.75 +$9.75 (+162.50%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$15.75

Day Range

$10.88$15.75

Year Range

$3.72$16.5

Market Cap

789.02M

AVG Volume

Trailing/Forward PE

-7.26/21.05

PEG ratio

-0.05

Dividend Yield

Next Earnings Date

2026-09-29

Primary Exchange

Other OTC

PE Ratio

GNFTF PE Ratio by quarter
Period	PE Ratio
Mar 24	10.75
Jan 24	12.41
Jan 24	12.39
Dec 23	12.24
Dec 23	11.02
Jun 23	4.14
May 23	4.45
Feb 23	23.9
Dec 22	19.79
Nov 22	17.27
Nov 22	20.8
Nov 22	21.55

Free Cash Flow Yield

GNFTF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-1.73%
Sep 26	-1.73%
Aug 26	-1.73%
Aug 26	-1.69%
Aug 26	-1.7%
Aug 26	-1.7%
Jul 26	-1.7%
Jul 26	-1.68%
Jul 26	-2.5%
Jul 26	-2.5%
Jul 26	-2.5%
Jun 26	-2.49%
Jun 26	-2.7%
Jun 26	-2.73%
Jun 26	-2.85%
May 26	-2.88%
May 26	-2.88%
May 26	-2.89%
May 26	-2.93%
May 26	-2.91%
Apr 26	-2.49%
Apr 26	-2.5%
Apr 26	-2.64%
Apr 26	-2.6%
Mar 26	-10.46%
Mar 26	-10.08%
Mar 26	-9.96%
Mar 26	-11.01%
Feb 26	-10.67%
Feb 26	-12.07%
Feb 26	-14.01%
Feb 26	-15.42%
Jan 26	-18.72%
Jan 26	-18.68%
Jan 26	-18.32%
Jan 26	-18.38%
Jan 26	-18.51%
Dec 25	-24.52%
Dec 25	-26.8%
Dec 25	-26.87%
Dec 25	-26.65%
Nov 25	-26.55%
Nov 25	-26.35%
Nov 25	-26.6%
Nov 25	-26.47%
Oct 25	-26.5%
Oct 25	-29.63%
Oct 25	-29.69%
Oct 25	-29.62%
Oct 25	-29.92%
Sep 25	-27.78%
Sep 25	-27.88%
Sep 25	-27.84%
Sep 25	-27.82%
Aug 25	-27.75%
Aug 25	-27.83%
Aug 25	-27.79%
Aug 25	-27.64%
Aug 25	-27.51%
Jul 25	-27.87%
Jul 25	-31.3%
Jul 25	-29.16%
Jul 25	-29.33%
Jun 25	-29.23%
Jun 25	-28.75%
Jun 25	-28.82%
Jun 25	-28.43%
May 25	-28.32%
May 25	-28.36%
May 25	-27.85%
May 25	-28.06%
May 25	-28.19%
Apr 25	-28.36%
Apr 25	-28.37%
Apr 25	-28.36%
Apr 25	-27.35%
Mar 25	-59.59%
Mar 25	-59.47%
Mar 25	-59.88%
Mar 25	-59.55%
Feb 25	-57.04%
Feb 25	-57.51%
Feb 25	-57.68%
Feb 25	-56.78%
Jan 25	-56.94%
Jan 25	-57.68%
Jan 25	-56.46%
Jan 25	-56.32%
Jan 25	-56.67%
Dec 24	-57.3%
Dec 24	-61.13%
Dec 24	-36.83%
Dec 24	-37.05%
Nov 24	-37.09%
Nov 24	-36.54%
Nov 24	-36.96%
Nov 24	-38.14%
Nov 24	-38.01%
Oct 24	-37.86%
Oct 24	-38.1%

Price to Sales

GNFTF Price to Sales by quarter
Period	Price to Sales
Sep 26	5.03
Sep 26	5.03
Aug 26	5.04
Aug 26	5.17
Aug 26	5.11
Aug 26	5.12
Jul 26	5.13
Jul 26	5.2
Jul 26	3.48
Jul 26	3.49
Jul 26	3.48
Jun 26	3.5
Jun 26	3.23
Jun 26	3.2
Jun 26	3.06
May 26	3.02
May 26	3.03
May 26	3.02
May 26	2.98
May 26	3
Apr 26	3.49
Apr 26	3.48
Apr 26	3.3
Apr 26	3.35
Mar 26	3.86
Mar 26	4.01
Mar 26	4.05
Mar 26	3.67
Feb 26	3.78
Feb 26	3.35
Feb 26	2.88
Feb 26	2.62
Jan 26	2.16
Jan 26	2.16
Jan 26	2.2
Jan 26	2.2
Jan 26	2.18
Dec 25	1.65
Dec 25	1.51
Dec 25	1.5
Dec 25	1.52
Nov 25	1.52
Nov 25	1.53
Nov 25	1.52
Nov 25	1.53
Oct 25	1.52
Oct 25	1.36
Oct 25	1.36
Oct 25	1.36
Oct 25	1.35
Sep 25	1.7
Sep 25	1.7
Sep 25	1.7
Sep 25	1.7
Aug 25	1.7
Aug 25	1.7
Aug 25	1.7
Aug 25	1.71
Aug 25	1.72
Jul 25	1.7
Jul 25	1.51
Jul 25	1.62
Jul 25	1.61
Jun 25	1.62
Jun 25	1.64
Jun 25	1.64
Jun 25	1.66
May 25	1.67
May 25	1.67
May 25	1.7
May 25	1.68
May 25	1.68
Apr 25	1.67
Apr 25	1.67
Apr 25	1.67
Apr 25	1.73
Mar 25	1.75
Mar 25	1.75
Mar 25	1.74
Mar 25	1.75
Feb 25	1.82
Feb 25	1.81
Feb 25	1.8
Feb 25	1.83
Jan 25	1.83
Jan 25	1.8
Jan 25	1.84
Jan 25	1.85
Jan 25	1.84
Dec 24	1.82
Dec 24	1.7
Dec 24	2.82
Dec 24	2.81
Nov 24	2.8
Nov 24	2.85
Nov 24	2.81
Nov 24	2.73
Nov 24	2.74
Oct 24	2.75
Oct 24	2.73

EV/EBITDA

GNFTF EV/EBITDA by quarter
Period	EV/EBITDA
Sep 26	416.36
Sep 26	415.77
Aug 26	416.85
Aug 26	426.71
Aug 26	422.38
Aug 26	422.7
Jul 26	423.7
Jul 26	429.17
Jul 26	296.92
Jul 26	297.44
Jul 26	297.01
Jun 26	298.21
Jun 26	277.17
Jun 26	274.89
Jun 26	264.01
May 26	261.3
May 26	261.65
May 26	261.11
May 26	257.99
May 26	259.26
Apr 26	297.75
Apr 26	296.77
Apr 26	282.55
Apr 26	286.57
Mar 24	6.87
Jan 24	8.32
Jan 24	8.31
Dec 23	8.17
Dec 23	7.11
Jun 23	12.14
May 23	13.57
Feb 23	193.99
Dec 22	98.64
Nov 22	40.33
Nov 22	122.19
Nov 22	139.45

Price/Operating Cashflow

GNFTF Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Mar 24	5.21
Jan 24	6.01
Jan 24	6
Dec 23	5.93
Dec 23	5.34
Jun 23	7.54
May 23	8.1

Price to Book

GNFTF Price to Book by quarter
Period	Price to Book
Mar 26	8.6
Mar 26	8.92
Mar 26	9.02
Mar 26	8.16
Feb 26	8.42
Feb 26	7.45
Feb 26	6.42
Feb 26	5.83
Jan 26	4.8
Jan 26	4.81
Jan 26	4.91
Jan 26	4.89
Jan 26	4.86
Dec 25	3.67
Dec 25	3.35
Dec 25	3.34
Dec 25	3.37
Nov 25	3.39
Nov 25	3.41
Nov 25	3.38
Nov 25	3.4
Oct 25	3.39
Oct 25	3.03
Oct 25	3.03
Oct 25	3.03
Oct 25	3
Sep 25	2.28
Sep 25	2.27
Sep 25	2.28
Sep 25	2.28
Aug 25	2.28
Aug 25	2.28
Aug 25	2.28
Aug 25	2.29
Aug 25	2.3
Jul 25	2.27
Jul 25	2.02
Jul 25	2.17
Jul 25	2.16
Jun 25	2.17
Jun 25	2.2
Jun 25	2.2
Jun 25	2.23
May 25	2.24
May 25	2.23
May 25	2.27
May 25	2.26
May 25	2.25
Apr 25	2.23
Apr 25	2.23
Apr 25	2.23
Apr 25	2.32
Mar 25	1.67
Mar 25	1.67
Mar 25	1.66
Mar 25	1.67
Feb 25	1.74
Feb 25	1.73
Feb 25	1.72
Feb 25	1.75
Jan 25	1.74
Jan 25	1.72
Jan 25	1.76
Jan 25	1.76
Jan 25	1.75
Dec 24	1.73
Dec 24	1.62
Dec 24	2.7
Dec 24	2.68
Nov 24	2.68
Nov 24	2.72
Nov 24	2.69
Nov 24	2.6
Nov 24	2.61
Oct 24	2.62
Oct 24	2.61
Oct 24	2.59
Oct 24	2.58
Sep 24	3.64
Sep 24	2.85
Sep 24	2.87
Sep 24	2.87
Aug 24	2.88
Aug 24	2.84
Aug 24	2.33
Aug 24	2.35
Aug 24	3.71
Jul 24	3.73
Jun 24	3.75
May 24	3.48
Apr 24	2.03
Mar 24	1.83
Jan 24	2.11
Jan 24	2.11
Dec 23	2.08
Dec 23	1.88
Jun 23	1.87
May 23	2
Feb 23	1.89
Dec 22	1.57

No video analysis for this stock yet. Request one from our team.

News: GNFTF

seekingalpha.com · 11 Sep 2026

Genfit S.A. (GNFTF) Discusses Developments and Guidance in MASH Diagnostics Transcript

globenewswire.com · 23 Jun 2026

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pretreated, high-unmet-need population of KRAS-mutated cholangiocarcinoma (CCA) patients who had progressed after one or two failed lines of prior standard-of-care therapy Phase 2 initiation on track for initiation in 2H26 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 23, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced positive Phase 1b results for GNS561 in combination therapy in patients with heavily pretreated cholangiocarcinoma, demonstrating a favorable safety and tolerability profile and early signs of antitumor activity. Clinical trial context and objective CCA is a rare and aggressive bile duct cancer, often diagnosed at an advanced stage.

globenewswire.com · 15 Jun 2026

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026. The quorum on first convening amounted to 32.13 % and shareholders approved all of the resolutions, with the exception of resolution n°26 which was rejected in accordance with the recommendations of the Board of Directors.